(Q38001275)

26 August 2017

title

The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases (English)

1 reference

26 August 2017

Tomblyn M

1

1 reference

26 August 2017

publication date

1 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

19

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

137-144

1 reference

Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

21 January 2018

Cancer-related symptoms

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Induction of transforming growth factor beta in hormonally treated human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Breakthrough pain: characteristics and impact in patients with cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Radiopharmaceuticals: when and how to use them to treat metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Treatment of bone pain secondary to metastases using samarium-153-EDTMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

(170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900208

Radioisotopes for metastatic bone pain

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD003347.PUB2

10.1177/107327481201900208

9 February 2024

Identifiers

DOI

0 references

1 reference